MiMedx Group, Inc.
NASDAQ:MDXGBiotechnology
+$0.08 today
- Market cap
- $464.04M
- Beta
- 1.46
- P/E (TTM)
- 17.8
- EPS (TTM)
- $0.21
Volume 1.51M
Average 1.55M
MDXG Other Non-Cash Items
Other non-cash adjustments that reconcile net income to operating cash flow.
MiMedx Group, Inc.NASDAQ: MDXG
Other Non-Cash Items · Q1 FY2026 · quarter ended Mar 2026
Other non-cash items growth accelerates
Q1 FY2026 other non-cash items of $1.91M rose 57.4% year over year, ahead of the -248.7% change in trailing-twelve-month other non-cash items. Over 3 fiscal years it compounded at +11.8% a year.
Context
- Other non-cash items amounted to 2.0% of revenue in FY2025, up 0.3 pp from a year earlier.
- Other non-cash items increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +57.4% holds above the trailing-twelve-month pace of -248.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Non-Cash Items history
USD · from the cash flow
- Latest · FY2025
- 8.42M USD
- Year-over-year change
- +244.8%
- 4-year CAGR
- -5.0%
| Period | Period end | Other Non-Cash Items | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.42M | +244.8% |
| FY2024 | 2024-12-31 | (5.81M) | -20.3% |
| FY2023 | 2023-12-31 | (4.83M) | -180.2% |
| FY2022 | 2022-12-31 | 6.03M | -41.7% |
| FY2021 | 2021-12-31 | 10.33M | — |
Other Non-Cash Items vs competitors
How MDXG compares with its peers on the latest reported figures
- MDXG's LTM Mar 2026 other non-cash items of $5.99M is the 6th largest of the 8 companies compared; the peer median is $18.53M.
- Its year-over-year change of -248.7% is the 7th highest of 8, against a peer median of +141.4%.
- Other non-cash items amounts to 1.5% of revenue for MDXG, versus a peer median of 7.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $47.4M | +606.5% | +135.3% | 320.7% | |
| LTM Mar 2026 | $35.97M | -21.0% | +13.5% | 7.0% | |
| LTM Dec 2025 | $27.2M | +141.4% | — | 102.4% | |
| LTM Jun 2026 | $18.53M | +3594.4% | +268.4% | — | |
| LTM Mar 2026 | $8.5M | +294.7% | +47.8% | 7.9% | |
| LTM Mar 2026 | $5.99M | -248.7% | +11.8% | 1.5% | |
| LTM Mar 2026 | $3.34M | +84.6% | +25.7% | 4.6% | |
| LTM Mar 2026 | $915.33K | -755.7% | — | 6.3% | |
| Peer median (excluding MDXG) | $18.53M | +141.4% | +47.8% | 7.5% | |
Competitors are the stored peer set for MDXG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (12.3M) | (19.95M) | 67.44M | 42M | 48.58M |
| Depreciation & Amortization | 5.18M | 4.05M | 3.43M | 6.04M | 14.88M |
| Deferred Income Tax | 0 | 0 | (37.8M) | 12.47M | 8.71M |
| Stock-Based Compensation | 14.16M | 11.33M | 16.96M | 16.93M | 16.4M |
| Change in Working Capital | (19.35M) | (8.01M) | (18.42M) | (5.43M) | (22.98M) |
| Accounts Receivables | (10.62M) | (5.94M) | (12.24M) | (2.55M) | (26.39M) |
| Inventory | (1.41M) | (1.79M) | (7.84M) | (2.36M) | (1.53M) |
| Accounts Payables | (159K) | 839K | 783K | (1.41M) | 2.12M |
| Other Working Capital | (7.17M) | (1.12M) | 876K | 885K | 2.83M |
| Other Non-Cash Items | 10.33M | 6.03M | (4.83M) | (5.81M) | 8.42M |
| Operating Cash Flow | (1.98M) | (17.89M) | 26.78M | 66.2M | 74M |
| Capital Expenditures | (3.22M) | (1.51M) | (1.99M) | (1.68M) | (1.03M) |
| Acquisitions (Net) | 0 | 24K | 0 | (7.86M) | (3.76M) |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (177K) | (1.15M) | (168K) | (38K) | 0 |
| Investing Cash Flow | (3.4M) | (2.66M) | (2.16M) | (9.58M) | (6.89M) |
| Debt Repayment | (38K) | (41K) | (52K) | (31.72M) | (1M) |
| Common Stock Issued | 0 | 651K | 997K | 0 | 0 |
| Common Stock Repurchased | (4.75M) | (1.19M) | (9.52M) | (2.64M) | (3.12M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.44M | (41K) | 9.46M | 159K | (1.29M) |
| Financing Cash Flow | (3.35M) | (580K) | (8.57M) | (34.2M) | (5.41M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (8.73M) | (21.13M) | 16.05M | 22.42M | 61.71M |
| Free Cash Flow | (5.2M) | (19.41M) | 24.79M | 64.52M | 72.97M |
MiMedx Group, Inc.
NASDAQ:MDXG
Intrinsic Alpha fair value
Locked
Current Price
$3.18
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.